Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: A review

Respiratory Research

Volumn 12, Issue 1, 2011, Pages

  Wu, Dongmei ^a,b   Lee, Dongwon ^b   Sung, Yong Kiel ^c,d  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b Chonbuk National University   (South Korea)

^c Korea Institute of Science and Technology Information (KISTI)   (South Korea)

^d Dongguk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IK 312532; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; RESPIRATORY TRACT AGENT; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIRCULATION; CONTROLLED DRUG RELEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; HEART RIGHT VENTRICLE FAILURE; HUMAN; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PULMONARY HYPERTENSION; RADIOIMMUNOASSAY; REVIEW; ANIMAL; IDIOPATHIC PULMONARY HYPERTENSION; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ASTHMA; HUMANS; HYPERTENSION, PULMONARY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM AGENTS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 79953757270     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-45     Document Type: Review

References (102)

1. Said SI, Mutt V: Polypeptide with broad biological activity: isolation from small intestine. Science 1970, 169:1217-8.
2. Said SI: Vasoactive intestinal peptide. J Endocrinol Invest 1986, 9:191-200.
3. Said SI, Mutt V, Yoshida T, Hara N: Vasoactive polypeptides from normal lung. Chest 1975, 67:44S.
4. Ghatei MA, Sheppard MN, O'Shaughnessy DJ, Adrian TE, McGregor GP, Polak JM, Bloom SR: Regulatory peptides in the mammalian respiratory tract. Endocrinology 1982, 111:1248-54.
5. Baraniuk JN, Lundgren JD, Okayama M, Mullol J, Merida M, Shelhamer JH, Kaliner MA: Vasoactive intestinal peptide in human nasal mucosa. J Clin Invest 1990, 86:825-31.
6. Dvoráková MC: Cardioprotective role of the VIP signaling system. Timely Top Med Cardiovasc Dis 2005, 9:E33.
7. Saga T, Said SI: Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans Assoc Am Physicians 1984, 97:304-10.
8. Smalley SG, Barrow PA, Foster N: Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. Clin Exp Immunol 2009, 157:225-34.
9. Onoue S, Misaka S, Aoki Y, Karaki S, Kuwahara A, Ohide A, Mizumoto T, Yamada S: Inhalable powder formulation of vasoactive intestinal peptide derivative, [R15,20,21, L17]-VIP-GRR, attenuated neutrophilic airway inflammation in cigarette smoke-exposed rats. Eur J Pharm Sci 2010, 41:508-14.
10. Szema AM, Hamidi SA, Lyubsky S, Dickman KG, Mathew S, Abdel-Razek T, Chen JJ, Waschek JA, Said SI: Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol 2006, 291:L880-6.
11. Onoue S, Yamada S, Yajima T: Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD. Peptides 2007, 28:1640-50.
12. Yuan JX, Rubin LJ: Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation 2005, 111:534-8.
13. Gandhi R, Baker N, Shek A, Yeh J, Bishop D: Pulmonary arterial hypertension: bridging the gap between efficacy, quality of life, and cost-effectiveness. Formulary 2010, 45:190-199.
14. Sahara M, Takahashi T, Imai Y, Nakajima T, Yao A, Morita T, Hirata Y, Nagai R: New insights in the treatment strategy for pulmonary arterial hypertension. Cardiovasc Drugs Ther 2006, 20:377-86.
15. Mannino DM, Buist AS: Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007, 370:765-73.
16. Berger WE, Cline DC: Asthma and COPD: definitions, epidemiology, and treatment guidelines. Postgrad Med 2005, 118:2-8.
17. Lundberg JM: Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Pharmacol Rev 1996, 48:113-78.
18. Henning RJ, Sawmiller DR: Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res 2001, 49:27-37.
19. Della NG, Papka RE, Furness JB, Costa M: Vasoactive intestinal peptide-like immunoreactivity in nerves associated with the cardiovascular system of guinea-pigs. Neuroscience 1983, 9:605-19.
20. Brum JM, Bove AA, Sufan Q, Reilly W, Go VL: Action and localization of vasoactive intestinal peptide in the coronary circulation: evidence for nonadrenergic, noncholinergic coronary regulation. J Am Coll Cardiol 1986, 7:406-13.
21. Slavíková J: Distribution of peptide-containing neurons in the developing rat right atrium, studied using immunofluorescence and confocal laser scanning. Neurochem Res 1997, 22:1013-21.
22. Kuncová J, Slavíková J, Reischig J: Distribution of vasoactive intestinal polypeptide in the rat heart: effect of guanethidine and capsaicin. Ann Anat 2003, 185:153-61.
23. Fahrenkrug J: VIP and autonomic neurotransmission. Pharmacol Ther 1989, 41:515-34.
24. Groneberg DA, Rabe KF, Fischer A: Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors. Eur J Pharmacol 2006, 533:182-94.
25. Dey RD, Shannon WA Jr, Said SI: Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects. Cell Tissue Res 1981, 220:231-8.
26. Lundberg JM, Fahrenkrug J, Hökfelt T, Martling CR, Larsson O, Tatemoto K, Anggård A: Co-existence of peptide HI (PHI) and VIP in nerves regulating blood flow and bronchial smooth muscle tone in various mammals including man. Peptides 1984, 5:593-606.
27. Laitinen A, Partanen M, Hervonen A, Pelto-Huikko M, Laitinen LA: VIP like immunoreactive nerves in human respiratory tract. Light and electron microscopic study. Histochemistry 1985, 82:313-9.
28. Fischer A, Hoffmann B: Nitric oxide synthase in neurons and nerve fibers of lower airways and in vagal sensory ganglia of man. Correlation with neuropeptides. Am J Respir Crit Care Med 1996, 154:209-16.
29. Fischer A, Canning BJ, Undem BJ, Kummer W: Evidence for an esophageal origin of VIP-IR and NO synthase-IR nerves innervating the guinea pig trachealis: a retrograde neuronal tracing and immunohistochemical analysis. J Comp Neurol 1998, 394:326-34.
30. Fischer A, Canning BJ, Kummer W: Correlation of vasoactive intestinal peptide and nitric oxide synthase with choline acetyltransferase in the airway innervation. Ann N Y Acad Sci 1996, 805:717-22.
31. Luts A, Sundler F: Peptide-containing nerve fibers in the respiratory tract of the ferret. Cell Tissue Res 1989, 258:259-67.
32. Cutz E, Chan W, Track NS, Goth A, Said SI: Release of vasoactive intestinal polypeptide in mast cells by histamine liberators. Nature 1978, 275:661-2.
33. Aliakbari J, Sreedharan SP, Turck CW, Goetzl EJ: Selective localization of vasoactive intestinal peptide and substance P in human eosinophils. Biochem Biophys Res Commun 1987, 148:1440-5.
34. Metwali A, Blum AM, Ferraris L, Klein JS, Fiocchi C, Weinstock JV: Eosinophils within the healthy or inflamed human intestine produce substance P and vasoactive intestinal peptide. J Neuroimmunol 1994, 52:69-78.
35. O'Dorisio MS, O'Dorisio TM, Cataland S, Balcerzak SP: Vasoactive intestinal polypeptide as a biochemical marker for polymorphonuclear leukocytes. J Lab Clin Med 1980, 96:666-72.
36. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, Block LH: Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003, 111:1339-46.
37. Haberl I, Frei K, Ramsebner R, Doberer D, Petkov V, Albinni S, Lang I, Lucas T, Mosgoeller W: Vasoactive intestinal peptide gene alterations in patients with idiopathic pulmonary arterial hypertension. Eur J Hum Genet 2007, 15:18-22.
38. Opstad PK: The plasma vasoactive intestinal peptide (VIP) response to exercise is increased after prolonged strain, sleep and energy deficiency and extinguished by glucose infusion. Peptides 1987, 8:175-8.
39. Burhol PG, Lygren I, Waldum HL: Radioimmunoassay of vasoactive intestinal polypeptide in plasma. Scand J Gastroenterol 1978, 13:807-13.
40. Bloom SR, Polak JM, Pearse AG: Vasoactive intestinal peptide and watery-diarrhoea syndrome. Lancet 1973, 2:14-6.
41. Gyöngyösi M, Németh J, Várkonyi T: Elevated levels of plasma vasoactive intestinal peptide in human acute myocardial infarction. Int J Cardiol 1996, 56:159-61.
42. Domschke S, Domschke W, Bloom SR, Mitznegg P, Mitchell SJ, Lux G, Strunz U: Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. Gut 1978, 19:1049-53.
43. Lundberg JM, Fahrenkrug J, Brimijoin S: Characteristics of the axonal transport of vasoactive intestinal polypeptide (VIP) in nerves of the cat. Acta Physiol Scand 1981, 112:427-36.
44. Said SI: Vasoactive intestinal polypeptide (VIP): current status. Peptides 1984, 5:143-50.
45. Goetzl EJ, Sreedharan SP, Turck CW, Bridenbaugh R, Malfroy B: Preferential cleavage of amino- and carboxyl-terminal oligopeptides from vasoactive intestinal polypeptide by human recombinant enkephalinase (neutral endopeptidase, EC 3.4.24.11). Biochem Biophys Res Commun 1989, 158:850-4.
46. Caughey GH, Leidig F, Viro NF, Nadel JA: Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Ther 1988, 244:133-7.
47. Lilly CM, Kobzik L, Hall AE, Drazen JM: Effects of chronic airway inflammation on the activity and enzymatic inactivation of neuropeptides in guinea pig lungs. J Clin Invest 1994, 93:2667-74.
48. Laburthe M, Couvineau A: Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP. Regul Pept 2002, 108:165-173.
49. Francis SH, Noblett BD, Todd BW, Wells JN, Corbin JD: Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase. Mol Pharmacol 1988, 34:506-17.
50. Arimura A: Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn J Physiol 1998, 48:301-31.
51. Carstairs JR, Barnes PJ: Visualization of vasoactive intestinal peptide receptors in human and guinea pig lung. J Pharmacol Exp Ther 1986, 239:249-255.
52. Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP: Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 2008, 123:398-410.
53. Harfi I, D'Hondt S, Corazza F, Sariban E: Regulation of human polymorphonuclear leukocytes functions by the neuropeptide pituitary adenylate cyclase-activating polypeptide after activation of MAPKs. J Immunol 2004, 173:4154-63.
54. Lara-Marquez ML, O'Dorisio MS, Karacay B: Vasoactive intestinal peptide (VIP) receptor type 2 (VPAC2) is the predominant receptor expressed in human thymocytes. Ann NY Acad Sci 2000, 921:45-54.
55. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. J Immunol 1999, 162:4685-96.
56. Delneste Y, Herbault N, Galea B, Magistrelli G, Bazin I, Bonnefoy JY, Jeannin P: Vasoactive intestinal peptide synergizes with TNF-alpha in inducing human dendritic cell maturation. J Immunol 1999, 163:3071-5.
57. Goetzl EJ, Voice JK, Shen S, Dorsam G, Kong Y, West KM, Morrison CF, Harmar AJ: Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide. Proc Natl Acad Sci USA 2001, 98:13854-13859.
58. Voice JK, Grinninger C, Kong Y, Bangale Y, Paul S, Goetzl EJ: Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol 2003, 170:308-314.
59. Morice A, Unwin RJ, Sever PS: Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects. Lancet 1983, 2:1225-7.
60. Colston JT, Freeman GL: Beneficial influence of vasoactive intestinal peptide on ventriculovascular coupling in closed-chest dogs. Am J Physiol 1992, 263:H1300-5.
61. Rigel DF, Grupp IL, Balasubramaniam A, Grupp G: Contractile effects of cardiac neuropeptides in isolated canine atrial and ventricular muscles. Am J Physiol 1989, 257:H1082-7.
62. Rigel DF, Lathrop DA: Vasoactive intestinal polypeptide facilitates atrioventricular nodal conduction and shortens atrial and ventricular refractory periods in conscious and anesthetized dogs. Circ Res 1990, 67:1323-33.
63. Henning RJ: Vagal stimulation during muscarinic and beta-adrenergic blockade increases atrial contractility and heart rate. J Auton Nerv Syst 1992, 40:121-9.
64. Henning RJ, Feliciano L, Coers CM: Vagal nerve stimulation increases right ventricular contraction and relaxation and heart rate. Cardiovasc Res 1996, 32:846-53.
65. Lucia P, Caiola S, Coppola A, Maroccia E, Belli M, Buongiorno A, De Martinis C: Early increase of vasoactive intestinal peptide in acute myocardial infarction. Am Heart J 1996, 132:187-9.
66. Groneberg DA, Springer J, Fischer A: Vasoactive intestinal polypeptide as mediator of asthma. Pulm Pharmacol Ther 2001, 14:391-401.
67. Hamasaki Y, Saga T, Mojarad M, Said SI: Vasoactive intestinal peptide counteracts leukotriene D4-induced contractions of guinea pig trachea, lung, and pulmonary artery. Trans Assoc Am Physicians 1983, 96:406-11.
68. Palmer JB, Cuss FM, Barnes PJ: VIP and PHM and their role in nonadrenergic inhibitory responses in isolated human airways. J Appl Physiol 1986, 61:1322-8.
69. Groneberg DA, Hartmann P, Dinh QT, Fischer A: Expression and distribution of vasoactive intestinal polypeptide receptor VPAC(2) mRNA in human airways. Lab Invest 2001, 81:749-55.
70. Coles SJ, Said SI, Reid LM: Inhibition by vasoactive intestinal peptide of glycoconjugate and lysozyme secretion by human airways in vitro. Am Rev Respir Dis 1981, 124:531-6.
71. Baraniuk JN, Lundgren JD, Okayama M, Mullol J, Merida M, Shelhamer JH, Kaliner MA: Vasoactive intestinal peptide in human nasal mucosa. J Clin Invest 1990, 86:825-31.
72. Webber SE, Widdicombe JG: The effect of vasoactive intestinal peptide on smooth muscle tone and mucus secretion from the ferret trachea. Br J Pharmacol 1987, 91:139-48.
73. Shimura S, Sasaki T, Ikeda K, Sasaki H, Takishima T: VIP augments cholinergic-induced glycoconjugate secretion in tracheal submucosal glands. J Appl Physiol 1988, 65:2537-44.
74. Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, Gomariz RP, Leceta J: Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med 2002, 80:16-24.
75. Undem BJ, Dick EC, Buckner CK: Inhibition by vasoactive intestinal peptide of antigen-induced histamine release from guinea-pig minced lung. Eur J Pharmacol 1983, 88:247-50.
76. O'Dorisio MS, Shannon BT, Fleshman DJ, Campolito LB: Identification of high affinity receptors for vasoactive intestinal peptide on human lymphocytes of B cell lineage. J Immunol 1989, 142:3533-6.
77. Berisha H, Foda H, Sakakibara H, Trotz M, Pakbaz H, Said SI: Vasoactive intestinal peptide prevents lung injury due to xanthine/xanthine oxidase. Am J Physiol 1990, 259:L151-5.
78. Misra BR, Misra HP: Vasoactive intestinal peptide, a singlet oxygen quencher. J Biol Chem 1990, 265:15371-4.
79. Leceta J, Gomariz RP, Martinez C, Abad C, Ganea D, Delgado M: Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Ann N Y Acad Sci 2000, 921:92-102.
80. Dunzendorfer S, Meierhofer C, Wiedermann CJ: Signalling in neuropeptide-induced migration of human eosinophils. J Leukoc Biol 1998, 64:828-34.
81. Dunzendorfer S, Feistritzer C, Enrich B, Wiedermann CJ: Neuropeptide-induced inhibition of IL-16 release from eosinophils. Neuroimmunomodulation 2002, 10:217-23. 2003
82. Delgado M: VIP: a very important peptide in T helper differentiation. Trends Immunol 2003,24(5):221-4.
83. Gunaydin S, Imai Y, Takanashi Y, Seo K, Hagino I, Chang D, Shinoka T: The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproteronol and nitroglycerine. Cardiovasc Surg 2002, 10:138-45.
84. Said SI: The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation. Ann N Y Acad Sci 2008, 1144:148-53.
85. Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, Lin RZ, Jiang YP, Chen JJ, Waschek JA, Kort S: Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 2007, 115:1260-8.
86. Popma JJ, Smitherman TC, Bedotto JB, Eichhorn EJ, Said SI, Dehmer GJ: Direct coronary vasodilation induced by intracoronary vasoactive intestinal peptide. J Cardiovasc Pharmacol 1990, 16:1000-6.
87. Frase LL, Gaffney FA, Lane LD, Buckey JC, Said SI, Blomqvist CG, Krejs GJ: Cardiovascular effects of vasoactive intestinal peptide in healthy subjects. Am J Cardiol 1987, 60:1356-61.
88. Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB: The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003, 124:474-81.
89. Zakynthinos E, Daniil Z, Papanikolaou G, Makris D: Pulmonary Hypertension in COPD: Pathophysiology and Therapeutic Targets. Curr Drug Targets 2011, 12:501-13.
90. Said SI, Hamidi SA, Gonzalez Bosc L: Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis? Eur Respir J 2010, 35:730-4.
91. Dorfmüller P, Perros F, Balabanian K, Humbert M: Inflammation in pulmonary arterial hypertension. Eur Respir J 2003, 22:358-63.
92. Stenmark KR, Mecham RP: Cellular and molecular mechanisms of pulmonary vascular remodeling. Annu Rev Physiol 1997, 59:89-144.
93. Homer RJ, Elias JA: Airway remodeling in asthma: therapeutic implications of mechanisms. Physiology (Bethesda) 2005, 20:28-35.
94. Sergejeva S, Hoshino H, Yoshihara S, Kashimoto K, Lötvall J, Lindén A: A synthetic VIP peptide analogue inhibits neutrophil recruitment in rat airways in vivo. Regul Pept 2004, 117:149-54.
95. Onoue S, Ohmori Y, Endo K, Yamada S, Kimura R, Yajima T: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar L2 cells. Eur JBiochem 2004, 271:1757-67.
96. Guan CX, Zhang M, Qin XQ, Cui YR, Luo ZQ, Bai HB, Fang X: Vasoactive intestinal peptide enhances wound healing and proliferation of human bronchial epithelial cells. Peptides 2006, 27:3107-14.
97. Misaka S, Aoki Y, Karaki S, Kuwahara A, Mizumoto T, Onoue S, Yamada S: Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats. Peptides 2010, 31:72-8.
98. Misaka S, Sato H, Aoki Y, Mizumoto T, Onoue S, Yamada S: Novel vasoactive intestinal peptide derivatives with improved stability protect rat alveolar L2 cells from cigarette smoke-induced cytotoxicity and apoptosis. Peptides 2011, 32:401-7.
99. Rubinstein I: Human VIP-alpha: an emerging biologic response modifier to treat primary pulmonary hypertension. Expert Rev Cardiovasc Ther 2005, 3:565-9.
100. Bolin DR, Cottrell J, Garippa R, Rinaldi N, Senda R, Simko B, O'Donnell M: Comparison of cyclic and linear analogs of vasoactive intestinal peptide. Drug Des Discov 1996, 13:107-14.
101. Schmidt DT, Rühlmann E, Waldeck B, Branscheid D, Luts A, Sundler F, Rabe KF: The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery. Naunyn Schmiedebergs Arch Pharmacol 2001, 364:314-20.
102. Lindén A, Hansson L, Andersson A, Palmqvist M, Arvidsson P, Löfdahl CG, Larsson P, Lötvall J: Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma. Thorax 2003, 58:217-21.